Venture financing in China surged with multiple large rounds: D3 Bio closed a $108M series B to advance a KRAS G12C program toward Phase III, while reports showed D3 Bio and Sanegene drew $100M+ rounds in a single venture roundup. The deals highlight deep regional capital backing for oncology and genomic platform companies. Investors and analysts said the funding reflects focused bets on small‑molecule oncology and diagnostics, and could accelerate trial timelines and global partnering activity. Observers will track how these financings affect cross‑border collaborations and competition in next‑generation targeted therapies.